Single Vial or Kit
Eloralintide
5MGAvailable as an individual research vial or a complete 10-vial research kit.
VIEW ELORALINTIDE 5MG →Eloralintide, also identified in scientific research as LY3841136, is an investigational selective, long-acting amylin receptor agonist.
Its development represents a different branch of metabolic research from compounds whose principal activity centers on incretin receptors such as GLP-1 or GIP.
The scientific interest surrounding Eloralintide comes largely from this distinction. Rather than simply extending the GLP-1 research category, Eloralintide focuses attention on the amylin receptor system.
Eloralintide has progressed through Phase 2 investigation and into multiple Phase 3 clinical studies. Published Phase 2 findings appeared in The Lancet, while current registered studies continue to evaluate the compound across several metabolic-research populations.
Over the last several years, metabolic research has been dominated by incretin signaling.
Semaglutide placed extraordinary attention on GLP-1 receptor agonism.
Tirzepatide expanded the field into combined GIP and GLP-1 receptor agonism.
Retatrutide pushed research further toward combined GIP, GLP-1 and glucagon receptor activity.
Eloralintide introduces a distinctly different research target:
Amylin is a naturally occurring pancreatic peptide hormone that is co-secreted with insulin.
It participates in metabolic signaling and has established physiological roles associated with satiety signaling, gastric emptying and glucagon regulation.
The amylin receptor system therefore represents a biologically distinct area of investigation from traditional incretin receptor research.
Eloralintide is notable because it was designed as a selective, long-acting amylin receptor agonist.
LY3841136 is the development designation used for Eloralintide throughout scientific literature and clinical-trial records.
Researchers searching for terms such as LY3841136 peptide, LY3841136 research, Eloralintide LY3841136 or LY3841136 amylin are referring to Eloralintide.
Published research describes Eloralintide as a potent, long-acting selective amylin receptor agonist. ([PubMed Central (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/?utm_source=chatgpt.com))
Eloralintide is no longer limited to early discovery work.
Phase 2 findings evaluating Eloralintide were published in The Lancet in 2025. ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2902155-5/abstract?utm_source=chatgpt.com))
The clinical-development program has since expanded into multiple Phase 3 studies, including registered studies in adults with obesity or overweight, with and without type 2 diabetes. ([Clinical Trials](https://clinicaltrials.gov/study/NCT07321886?utm_source=chatgpt.com))
Additional research programs are examining Eloralintide in other populations, further expanding the scientific program surrounding the molecule. ([Clinical Trials](https://clinicaltrials.gov/study/NCT07353931?utm_source=chatgpt.com))
These compounds should not be treated as interchangeable. They are associated with different receptor targets and different research profiles.
| Compound | Primary Research Target | Research Category |
|---|---|---|
| Eloralintide | Amylin receptors | Selective amylin receptor agonist |
| Semaglutide | GLP-1 receptor | GLP-1 receptor agonist |
| Tirzepatide | GIP + GLP-1 receptors | Dual receptor agonist |
| Retatrutide | GIP + GLP-1 + glucagon receptors | Triple receptor agonist |
Eloralintide has also been investigated alongside tirzepatide within Lilly's clinical-development program.
This is scientifically notable because the two compounds focus on distinct receptor systems.
Tirzepatide is associated with dual GIP and GLP-1 receptor agonism, whereas Eloralintide is being investigated through selective amylin receptor agonism.
Lilly has conducted clinical research evaluating Eloralintide both alone and together with tirzepatide. ([Lilly Trials](https://trials.lilly.com/en-US/trial/590708?utm_source=chatgpt.com))
Royal Peptides offers Eloralintide research material in two standard strengths, allowing laboratories and research buyers to select the format that fits their project requirements.
Available as an individual research vial or a complete 10-vial research kit.
VIEW ELORALINTIDE 5MG →Higher-content research format available individually or in a full 10-vial kit.
VIEW ELORALINTIDE 10MG →
10 × 5mg research vials
Total nominal research material: 50mg.
10 × 10mg research vials
Total nominal research material: 100mg.
Royal Peptides offers higher-volume Eloralintide purchasing for qualifying laboratories, research suppliers, resellers and established wholesale buyers.
Qualifying wholesale orders can mix products across the Royal Peptides catalog to meet the wholesale minimum.
This allows higher-volume buyers to add Eloralintide alongside other research products within the same wholesale order.
Eloralintide preorder inventory is currently available across 5mg, 10mg, single-vial, 10-vial-kit and qualifying wholesale formats.
Preordering allows research buyers to reserve inventory from the incoming batch ahead of standard stocked availability.
PREORDER ELORALINTIDE →Independent analytical verification remains central to our quality program.
Product identification and batch documentation are especially important with emerging research compounds.
Established domestic fulfillment helps simplify research-material ordering.
Order smaller research quantities without committing to a complete kit.
Higher-volume standard research formats are available in both 5mg and 10mg.
Qualifying buyers have a direct route to larger-volume Eloralintide orders.
Eloralintide has been described in published scientific literature as a potent, long-acting selective amylin receptor agonist. ([PubMed Central (PMC)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/?utm_source=chatgpt.com))
Phase 2 research was published in The Lancet in 2025. ([The Lancet](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2825%2902155-5/abstract?utm_source=chatgpt.com))
Registered Phase 3 studies are evaluating Eloralintide in adults with obesity or overweight, including populations with and without type 2 diabetes. ([Clinical Trials](https://clinicaltrials.gov/study/NCT07321886?utm_source=chatgpt.com))
Lilly's clinical program has also evaluated Eloralintide both alone and in combination with tirzepatide. ([Lilly Trials](https://trials.lilly.com/en-US/trial/590708?utm_source=chatgpt.com))
Eloralintide represents a distinct and rapidly developing direction in metabolic research centered on selective amylin receptor agonism.
Eloralintide remains an investigational compound and is not FDA approved.
Royal Peptides products are sold strictly for laboratory research purposes only and are not intended for human consumption, medical use, diagnosis, treatment or veterinary use.
Royal Peptides is not affiliated with Eli Lilly and Company. References to Eloralintide, LY3841136, Lilly, clinical studies or published research are provided solely to describe independent third-party scientific research.
